

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/539,543	06/16/2005	Stefan Berg	100925-1P US	7996	
22466 7590 62/11/2009 ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY			EXAM	EXAMINER	
			MURRAY, JEFFREY H		
1800 CONCORD PIKE WILMINGTON, DE 19850-5437		ART UNIT	PAPER NUMBER		
		1624			
			MAIL DATE	DELIVERY MODE	
			02/11/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Application No. Applicant(s) 10/539 543 BERG ET AL. Office Action Summary Examiner Art Unit JEFFREY H. MURRAY 1624 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 17 November 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 4-7 and 15-19 is/are pending in the application. 4a) Of the above claim(s) 5.6 and 15-19 is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) 4 and 7 is/are rejected. 7) Claim(s) \_\_\_\_\_ is/are objected to. 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

PTOL-326 (Rev. 08-06)

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date 11/17/2008

Notice of Draftsperson's Patent Drawing Review (PTO-948)
 Information Disclosure Statement(s) (PTO/S5/08)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

Notice of Informal Patent Application

Application/Control Number: 10/539,543 Page 2

Art Unit: 1624

compounds in therapy.

### DETAILED ACTION

### Election/Restrictions

- 1. This action is in response to a non-final action filed on November 17, 2008. There are nine claims pending and two claims under consideration. Claims 1-3, 8-14 and 20 have been cancelled. Claims 5, 6, and 15-19 are withdrawn. This is the second action on the merits. The present invention relates to new compounds of formula I, to pharmaceutical formulations containing said compounds and to the use of said
- This application contains claims 5, 6, and 15-19 drawn to an invention nonelected without traverse in the reply filed on June 16, 2008. A complete reply to the final rejection should include cancellation of nonelected claims or other appropriate action.

### Withdrawn Rejections/Objections

Applicant is notified that any outstanding rejection/objection that is not expressly
maintained in this office action has been withdrawn or rendered moot in view of
applicant's amendments and/or remarks.

## Claim Objections

3. Claim 4 is objected to because of the following informalities: Claim 4 does not end with a period. Under MPEP 608.01(m), "Each claim begins with a capital letter and ends with a period." Appropriate correction is required.

Page 3

Application/Control Number: 10/539,543

Art Unit: 1624

### Double Patenting

4. Claims 4 and 7 remain rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent Publication Application No. 2006/0173014. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 1 of U.S. Patent Publication Application No. 2006/0173014 embraces the instant claims 4 and 7.

Applicants have asked this rejection be held in abeyance until all other rejections have been withdrawn. This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

#### Conclusion

- 5. Claims 4 and 7 are rejected.
- THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey H. Murray whose telephone number is (571) 272-9023. The examiner can normally be reached on Mon.-Thurs. 7:30-6pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jeffrey H Murray/ Patent Examiner Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner, Art Unit 1624